Dragos N.
- Country
- Romania
- Department
- Ambulatoriul de pneumologie
Research Overview
- Therapeutic Equivalence of CHF5993 Combination Therapy Using HFA-152a Versus HFA-134a in Adults With Mild to Moderate Asthma
- A Phase 2b Dose-Ranging Study of Oral KT-621 in Adults with Uncontrolled Moderate to Severe Eosinophilic Asthma
- Phase 3 Study of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
Data & Insights
Has run more than one trial at 253 of 541 partner sites.
Specializations
Asthma and severe airway inflammation
Dragos Nicolosu is involved in clinical research on asthma across mild, moderate, and severe disease, with emphasis on uncontrolled asthma, eosinophilic asthma, and allergic airway inflammation. His work includes studies in patients with persistent symptoms despite inhaled therapy and in those with high-risk exacerbation patterns.
- Moderate-to-severe asthma
- Severe uncontrolled asthma
- Uncontrolled moderate to severe eosinophilic asthma
- FeNO-guided airway inflammation
His research landscape also includes therapeutic evaluation of inhaled and biologic approaches aimed at improving symptom control, reducing exacerbations, and preserving lung function in chronic airway disease.
COPD and chronic bronchitic disease
He is active in studies centered on chronic obstructive pulmonary disease and chronic bronchitis, with attention to bronchodilation, maintenance treatment, and exacerbation prevention. This area reflects a sustained interest in therapies for obstructive lung disease in routine pulmonary care.
- COPD
- Chronic bronchitis
- Triple inhaled therapy
- Exacerbation reduction
His trial portfolio also includes comparative evaluation of inhaled combinations designed to support airflow improvement and day-to-day respiratory stability in adults with chronic obstructive disease.
COVID-19 and respiratory infection care
Dragos Nicolosu has participated in research involving COVID-19 in outpatients, linking infectious disease management with respiratory medicine practice. This area reflects interest in treatment strategies for acute viral illness in patients at risk of clinical deterioration.
- COVID-19 outpatients
- All-cause hospitalization
- All-cause death
- Supportive care
His involvement extends the clinical scope of pulmonary research into infection-related outcomes relevant to ambulatory respiratory practice.
Chronic hepatitis B and antiviral therapy
He is also involved in studies on chronic hepatitis B, including treatment approaches for patients receiving established antiviral background therapy and pediatric populations with persistent infection. This adds a liver-disease dimension to his clinical research profile.
- Chronic hepatitis B infection
- Antiviral therapy
- Pediatric hepatitis B
- Sequential immunotherapy
His work in this field is centered on therapeutic strategies intended to improve virologic control and long-term management of chronic infection.
Idiopathic pulmonary fibrosis and lung function decline
Dragos Nicolosu’s research includes idiopathic pulmonary fibrosis, with focus on preserving respiratory capacity and limiting progression of fibrotic lung disease. This area broadens his portfolio beyond obstructive disorders into interstitial lung pathology.
- Idiopathic pulmonary fibrosis
- Forced vital capacity
- Lung function decline
- Fibrotic lung disease
His clinical interests here are aligned with therapies evaluated for maintaining pulmonary function in patients with progressive respiratory impairment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.